RAPGEF3 and cardiac hypertrophy: Of note, EPAC1 is increased at the onset of cardiac hypertrophy in a PKA-independent manner and EPAC1 pharmacological or genetic inhibition protects mice against cardiac hypertrophy and fibrosis during chronic β-AR stimulation [48,55,56].